(Q37484583)

20 August 2017

1 reference

title

Therapeutic challenges in primary CNS lymphoma (English)

1 reference

20 August 2017

2

Lauren E Abrey

1 reference

20 August 2017

Patrick G Morris

1

1 reference

20 August 2017

1 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

8

1 reference

20 August 2017

6

1 reference

20 August 2017

581-592

1 reference

Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Treatment for primary CNS lymphoma: the next step

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Long-term survival in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Treatment-related neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Combined modality therapy for primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

A multicenter study of treatment of primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

First-line autologous stem cell transplantation in primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Prospective trial on topotecan salvage therapy in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

PCV salvage chemotherapy for recurrent primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Temozolomide as salvage treatment in primary brain lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Current status and future of relapsed primary central nervous system lymphoma (PCNSL).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

The clinical spectrum of ocular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Decreasing incidence rates of primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970091-2

7 January 2021

10.1016/S1474-4422(09)70091-2

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19446277